

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C08B 37/10, A61K 31/725	A1	(11) International Publication Number: WO 98/55515 (43) International Publication Date: 10 December 1998 (10.12.98)
(21) International Application Number: PCT/CA98/00548 (22) International Filing Date: 5 June 1998 (05.06.98) (30) Priority Data: 60/072,098 6 June 1997 (06.06.97) US (71) Applicant (for all designated States except US): HAMILTON CIVIC HOSPITALS RESEARCH DEVELOPMENT, INC. [CA/CA]; 711 Concession Street, Hamilton, Ontario L8V 1C3 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): WEITZ, Jeffrey [CA/CA]; 54 Carluke Road East, Ancaster, Ontario L9G 3L1 (CA). HIRSH, Jack [CA/CA]; 21 Cottage Avenue, Hamilton, Ontario L8P 4G5 (CA). (74) Agents: ROBINSON, J., Christopher et al.; Fetherstonhaugh & Co., Vancouver Centre, Suite 2200, 650 West Georgia Street, Box 11560, Vancouver, British Columbia V6B 4N8 (CA).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: MODIFIED LOW MOLECULAR WEIGHT HEPARIN THAT INHIBITS CLOT ASSOCIATED COAGULATION FACTORS		
(57) Abstract <p>The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, <i>inter alia</i>, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.</p>		